IL6 and neoplasm: Triptolide is a diterpenoid triepoxide derived from the herb Tripterygium wilfordii, which has been used as a natural agent; preclinical studies have suggested that triptolide treatment may inhibit the migration-, formation-, and invasion-promoting action of CAFs in GC [104]; in addition, this agent has been shown to downregulate microRNA-301a expression, while upregulating microRNA-149 expression in CAFs, a process leading to increased production of tumor-suppressive factors and to the inhibition of the secretion of the oncogenic IL-6.